Envista Holdings Corp

Envista Holdings Corp (NVST) Market Cap

Envista Holdings Corp has a market capitalization of $4.56B.

Financials based on reported quarter end 2025-12-31

Price: $27.84

0.90 (3.34%)

Market Cap: 4.56B

NYSE · time unavailable

CEO: Paul A. Keel

Sector: Healthcare

Industry: Medical - Equipment & Services

IPO Date: 2019-09-18

Website: http://www.envistaco.com

Envista Holdings Corp (NVST) - Company Information

Market Cap: 4.56B · Sector: Healthcare

Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

Analyst Sentiment

68%
Buy

Based on 14 ratings

Analyst 1Y Forecast: $25.32

Average target (based on 3 sources)

Consensus Price Target

Low

$19

Median

$25

High

$35

Average

$27

Downside: -3.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ENVISTA HOLDINGS CORP (NVST) — Investment Overview

🧩 Business Model Overview

Envista Holdings Corporation (NVST) is a leading global provider of dental products, technologies, and services. The company was established via the consolidation of prominent brands in the dental industry and operates as a pure-play dental technology and solutions provider. Envista’s business model revolves around delivering comprehensive dental solutions for professionals, clinics, and laboratories. It operates through two primary segments: Specialty Products & Technologies and Equipment & Consumables. The company serves dentists, orthodontists, dental laboratories, and distributors across more than 150 countries. Envista is committed to innovation, focusing on advancing dental clinical procedures and patient outcomes. By leveraging a portfolio of premium and value-oriented brands, the corporation addresses the full spectrum of dental needs, from diagnosis and prevention to restoration and orthodontics. Its broad customer reach and recurring product demand make its business model resilient to economic cycles and technological shifts.

💰 Revenue Streams & Monetisation Model

Envista generates revenue primarily through the sale of dental implants, orthodontic products (including clear aligners), dental equipment, imaging systems, and consumables such as adhesives, cement, and clinical supplies. Its specialty solutions include implant systems, orthodontic solutions, and digital imaging products. The Equipment & Consumables segment provides hand instruments, rotary tools, preventive care products, and other dental operatory essentials. The company’s monetization model is enhanced by a strong base of repeat and recurring sales, particularly through consumables and digital workflow systems that require ongoing product replacement and software updates. Additionally, service contracts, extended warranties, and consultancy/training programs provide a supplementary stream of revenue. Strategic pricing, product bundling, and close partnerships with dental practices and distribution networks support consistent monetization across markets.

🧠 Competitive Advantages & Market Positioning

Envista differentiates itself through a diversified portfolio of reputable and globally recognized brands, such as Nobel Biocare, Ormco, and KaVo. These brands have long-standing relationships with dental professionals and command significant loyalty within the industry. The company’s experience in digital transformation for dental practices — including imaging, diagnostics, and workflow integration — positions it as a thought leader amid the increasing adoption of digitized dental care. Another core competitive advantage is Envista’s scale and global distribution infrastructure, enabling efficient customer outreach and supply chain resiliency. Its direct sales force and distributor relationships provide access to both emerging and developed markets. Additionally, the company invests heavily in R&D, which sustains its pipeline of next-generation implants, orthodontic solutions, and digital equipment. Product breadth allows Envista to capture value across multiple steps of the dental care continuum. Cross-selling opportunities between its various offerings further entrench customer relationships and widen addressable market opportunities.

🚀 Multi-Year Growth Drivers

Several secular and company-specific growth drivers underpin Envista’s long-term outlook: - **Rising Global Dental Demand:** Aging populations, increased awareness of oral health, and growing disposable incomes in emerging markets are driving elevated demand for dental procedures worldwide. - **Technological Innovation:** The migration to digital dentistry, including CAD/CAM restorations, 3D imaging, and digital orthodontic solutions such as clear aligners, supports ongoing demand for Envista’s high-tech offerings. - **Implant and Orthodontics Penetration:** Dental implants and orthodontic treatments remain underpenetrated relative to global needs. Expanding access and increasing aesthetic focus (e.g., adult orthodontics) provide a long-term tailwind. - **Geographic Expansion:** The company is actively expanding into high-growth international markets, where dental infrastructure investment and middle-class expansion are robust. - **Aftermarket & Recurring Revenue:** The continuous requirement for consumables, spare parts, services, and software subscriptions ensures a high proportion of reliable, recurring sales. - **M&A Opportunities:** Envista’s experience with integrations and its scalable infrastructure could be leveraged for inorganic growth through acquisitions of complementary technologies or geographic expansions.

⚠ Risk Factors to Monitor

Several risks require attention: - **Market Competition:** The dental supply industry is highly competitive, with global and regional players, including Dentsply Sirona, Straumann, and Align Technology, vying for share. Price pressure and rapid technological innovation can challenge margins. - **Macroeconomic Sensitivity:** Reduced discretionary spending during economic downturns may affect procedure volumes, particularly elective orthodontics and implants. - **Regulatory Environment:** Medical device approval processes, compliance risks, and shifting healthcare reimbursement structures may impact market access and cost structures. - **Supply Chain Disruptions:** Global manufacturing, logistics constraints, or raw material shortages could hamper timely fulfillment and profitability. - **Execution Risk:** Integration challenges related to acquisitions or large-scale product rollouts could impact operational effectiveness.

📊 Valuation & Market View

Envista is typically valued by the market on a mix of EV/EBITDA and price-to-earnings multiples, relative to its peers in the dental technology and medical devices sector. Its valuation reflects expectations for steady growth, robust free cash flow generation, and revenue resilience stemming from its recurring consumables and services sales. The company’s historic investments in innovation and brand equity grant it a valuation premium, though cyclical demand for elective dental treatments, as well as macroeconomic headwinds, can add volatility to market sentiment. Investor focus tends to be on margins, organic growth rates (particularly in specialty and digital solutions), and execution of geographic expansion and operational improvement initiatives. Additionally, the market closely observes Envista’s ability to balance shareholder returns (via share repurchases or dividends) with sustained investment in product development and M&A.

🔍 Investment Takeaway

Envista Holdings Corp presents an attractive long-term investment case as a diversified, globally scaled dental technology leader. Its portfolio of category-leading brands, deep relationships within the dental professional community, and commitment to innovation underpin resilient financial performance and competitive positioning. Emerging trends in digital dentistry, increasing awareness of oral health, and the underpenetration of dental implants and orthodontics serve as powerful growth catalysts over the coming years. While investors must weigh the risks posed by competition, regulatory requirements, and economic cyclicality, Envista’s steady expansion into digital solutions, recurring revenue focus, and prudent capital allocation create potential for value creation. For investors seeking exposure to global med-tech and the defensive growth profile of dental healthcare, Envista represents a compelling, well-diversified candidate.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For the quarter ending December 31, 2025, NVST reported revenue of $750.6 million, with a net income of $32.9 million, resulting in an EPS of $0.20. The company's net margin stands at 4.4%, while it generated $67.9 million in free cash flow. Year-over-year revenue growth is not directly specified, but the financial results point to robust operational efficiency and a strong cash position. Profitability is indicative of the company’s ability to manage expenses relative to its revenue effectively. The operating cash flow of $78.7 million versus capital expenditures of $10.8 million supports sound cash flow management, contributing to a healthy free cash flow generation. NVST manages a relatively modest net debt of $386 million, underscoring its solid balance sheet with total assets of $5.679 billion against liabilities of $2.572 billion. With no dividends paid but significant buybacks of $100.3 million, the company is focusing on increasing shareholder value through capital returns. Analysts' price targets suggest mixed sentiment, with a consensus target of $27.22, indicating potential for share price growth. Overall, NVST's valuation metrics will be key for assessing its market positioning amid its strategic financial maneuvers."

Revenue Growth

Neutral

Revenue stability is observed, but specific YoY growth details are needed to understand the trend and drivers.

Profitability

Positive

Profitable operations with a 4.4% net margin; efficient cost management results in stable EPS.

Cash Flow Quality

Good

Strong free cash flow, supported by significant operating cash flow exceeding capex; liquidity is high.

Leverage & Balance Sheet

Good

Solid balance sheet with net debt at a manageable level; high asset coverage for liabilities ensures resilience.

Shareholder Returns

Positive

Aggressive stock repurchases boost shareholder value, though no dividends limit returns for income-focused investors.

Analyst Sentiment & Valuation

Neutral

Analyst targets indicate a potential undervaluation, though variability in estimates reflects uncertain sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So What? Management delivered strong Q4/Q2025 execution but repeatedly highlighted that reported growth and margins benefited from non-recurring items (Spark deferral effects, prior-year comps, and FX timing). In Q&A, the tone shifts from “confidence in 2026” to explicit uncertainty: macro volatility (tariffs/interest rates/consumer confidence) and China VBP timing (China ~7% of sales, with Ortho likely H2 and Implants likely Q2) are framed as the key variables that can swing quarter-by-quarter orders. On profitability, the street’s focus on upside/downside became concrete: guidance implies only ~50–100 bps of margin expansion in 2026 even with productivity, while tariffs (~$10M next year run-rate; ~$40M annualized currently-in-effect) and ongoing reinvestment cap margin leverage. Management’s confidence is still intact (2–4% core growth; 7–13% EBITDA; EPS $1.35–$1.45), but the analyst pressure centers on whether the “step-up” in Q4 (~10.8% core vs implied ~2%) is sustainable amid these named hurdles.

AI IconGrowth Catalysts

  • Increased new product activity and clinical training
  • 30% more customers trained in 2025
  • Close to $100M revenue from products introduced in last 12 months
  • Diagnostics market turned positive in H2 2025; third consecutive quarter of Diagnostics growth
  • Spark momentum: Spark profitable in Q3 and continued execution into Q4

Business Development

  • China VBP programs (timing variable): expect Ortho first-round VBP sometime in H2 2026 and Implants second-round VBP likely in Q2 2026
  • Pricing / margin actions supported by supply chain adjustments (no named vendors disclosed)

AI IconFinancial Highlights

  • Q4 sales: $751M; core sales +10.8% (FX added ~400 bps); reported growth +15%
  • Q4 adjusted EPS: $0.38, up $0.14 YoY (up >50% cited vs Q4 '24)
  • Q4 adjusted gross margin: 55.0%, down 220 bps YoY (driven by FX transaction benefit in Q4 2024)
  • Q4 adjusted EBITDA margin: 14.8%, up 90 bps YoY (benefits from volume/price/productivity partially offset by investments and prior-year FX)
  • Q4 free cash flow: $92M, down ~$32M YoY (higher Q4 2025 CapEx; working-capital improvement in prior year)
  • Full-year 2025: sales $2.7B; core sales +6.5%; adjusted EBITDA margin 13.7% (+190 bps); adjusted EPS $1.19 (+$0.46 YoY); free cash flow conversion 114%
  • Margin bridge highlights (Q4): +330 bps from volume/mix/Spark deferral benefit; +260 bps from price actions; +100 bps productivity (supply chain + G&A reductions); -160 bps gross tariff expense (~$10M); +170 bps reinvestment into S&M/R&D; -270 bps FX headwind
  • 2025 tariff impact disclosed: ~$30M headwind in 2025

AI IconCapital Funding

  • Share repurchase: $250M program initiated early 2025
  • Q4 repurchases: ~$24M cash to buy 1.2M shares
  • Full-year repurchases: $166M; >9M shares at avg ~$18/share
  • Balance sheet: net debt / adjusted EBITDA ~0.6x

AI IconStrategy & Ops

  • EBS continuous improvement drove G&A reduction: over $35M (about 10%) in 2025 while maintaining safety/quality/customer service
  • Investing productivity gains back into growth: ~$170 bps reinvestment into sales/marketing/R&D in Q4
  • CapEx higher in 2025 (reduced FCF vs prior year in Q4); no specific CapEx number provided

AI IconMarket Outlook

  • 2026 guidance: core revenue growth 2% to 4%; adjusted EBITDA growth 7% to 13%; adjusted EPS $1.35 to $1.45; free cash conversion ~100%
  • 2026 quarterly cadence: faster Q1 and slower Q4 due to selling-day effects (Q1 has +4 selling days vs 2025; Q4 has -4)
  • Foreign exchange assumption: uses December ending exchange rates; EUR 1 = USD 1.17 implying ~1.5% full-year FX revenue benefit
  • Remaining Spark deferral tailwind in H1 2026: ~$15M
  • Pricing: expects pricing to moderate after laps of tariff-related increases (no material tariff changes modeled)

AI IconRisks & Headwinds

  • Macro volatility risk called out as unusually wide confidence interval drivers: tariffs, interest rates, consumer confidence impacting dental demand
  • China risk: China is ~7% of total sales; VBP timing delays create quarter-by-quarter uncertainty (timing varies due to complex, multi-province/national VBPs and hospital participation)
  • Tariff headwind: guided ~a $10M/quarter run-rate in 2H 2025 implying ~a $10M annualized headwind next year (2026)
  • 2026 tariff expectation: ~$40M from tariffs currently in effect (annualization) and management expects to cover via price increases, cost reductions, and supply chain adjustments
  • Margin risk components on 2026 EBITDA: China viewed as margin rate headwind and slight profit dollar headwind; investments continue (R&D, S&M) at pace of business performance
  • FX margin risk: less predictable, but management expects year-on-year FX to be a tailwind in 2026 because prior-year transaction balance sheet revaluation losses drove the 1H 2025 distortion

Sentiment: MIXED

Note: This summary was synthesized by AI from the NVST Q4 2025 (reported 2026-02-06) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (NVST)

© 2026 Stock Market Info — Envista Holdings Corp (NVST) Financial Profile